Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study
Rheumatology International · 2024
DOI: 10.1007/s00296-024-05584-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, 2024. Verfasst von Anne Bech-Drewes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. anne.drewes@clin.au.dk. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Gout, Cross-Over Studies, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aarhus University Hospital.
Abstract (Originalsprache)
Gout attacks are treated with uric-lowering and anti-inflammatory drugs. In patients with gout, non-steroidal anti-inflammatory drugs (NSAIDs) could be both cardiovascular beneficial, due to their anti-inflammatory actions, and cardiovascular hazardous, due to their prothrombotic, hypertensive, and proarrhythmic side effects. We, therefore, examined the risk of cardiovascular events associated with NSAID use in patients with gout. We conducted a nationwide, population-based case-crossover study of all Danes ≥ 18 years of age with first-time gout during 1997–2020, who experienced a cardiovascular event (myocardial infarction, ischemic stroke, congestive heart failure, atrial fibrillation/flutter, or cardiovascular death) ( n = 59,150). The exposure was use of NSAIDs, overall and according to type (ibuprofen, naproxen, or diclofenac). We used the dates 300, 240, 180, and 120 before the outcome date as reference dates. We used the Mantel–Haenszel method to calculate odds ratios (ORs) with 95% confidence intervals (CIs) of the association between NSAID use and cardiovascular events. NSAID use was overall associated with 12% decreased odds of a cardiovascular event (OR = 0.88, 95% CI: 0.85–0.91). This decreased odds ratio was observed for the use of ibuprofen (OR = 0.92, 95% CI: 0.88–0.97) and naproxen (OR = 0.85, 95% CI: 0.74–0.97), but not for the use of diclofenac (OR = 0.97, 95% CI: 0.90–1.05). Overall, use of NSAIDs was associated with decreased odds of all the individual components of the composite outcome. NSAIDs were not associated with an increased cardiovascular event rate when used in gout patients. Ibuprofen and naproxen appeared to have better cardiovascular risk profiles than diclofenac.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. anne.drewes@clin.au.dk.
- Department of Clinical Medicine, Aarhus University, Olof Palmes Allé 43, 8200, Aarhus, Denmark. anne.drewes@clin.au.dk.
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Olof Palmes Allé 43, 8200, Aarhus, Denmark.
- Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Cardiology, Gødstrup Regional Hospital, Aarhus, Denmark.
ORCID-Profile: Anne Bech-Drewes
Förderung
- Aarhus University Hospital
Zitieren
APA
Bech-Drewes, A., Bonnesen, K., Hauge, E. M., & Schmidt, M. (2024). Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study. Rheumatology International. https://doi.org/10.1007/s00296-024-05584-7
Vancouver
Bech-Drewes A, Bonnesen K, Hauge EM, Schmidt M. Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study. Rheumatology International. 2024. doi:10.1007/s00296-024-05584-7
BibTeX
@article{BechDrewes2024,
author = {Bech-Drewes, Anne and Bonnesen, Kasper and Hauge, Ellen-Magrethe and Schmidt, Morten},
title = {Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study},
journal = {Rheumatology International},
year = {2024},
doi = {10.1007/s00296-024-05584-7}
}
EUVIMED